Candriam SCA’s Juno Therapeutics, Inc. JUNO Stock Holding History

Candriam SCA’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-141,000	Closed	-$6.45M	–	804
2017 Q4	$6.45M	Buy	141,000 +20,000	+17%	+$998K	0.11%	222
2017 Q3	$5.43M	Buy	+121,000	New	+$4.13M	0.09%	249
2017 Q2	–	Sell	-69,000	Closed	-$1.53M	–	727
2017 Q1	$1.53M	Sell	69,000 -11,000	-14%	-$236K	0.03%	490
2016 Q4	$1.51M	Hold	80,000	–	–	0.03%	424
2016 Q3	$2.4M	Buy	+80,000	New	+$2.49M	0.06%	323

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Candriam SCA's JUNO Position: Q1 2018 in Review

Candriam SCA sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 141,000 shares — an estimated $6.45M sold.

Candriam SCA first reported a position in JUNO in Q3 2016 and held it in 5 quarters. The position peaked at $6.45M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Candriam SCA reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Candriam SCA sold 141,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $6.45M.
Candriam SCA first reported a position in Juno Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
Candriam SCA's Juno Therapeutics, Inc. position peaked at $6.45M in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Candriam SCA's 13F filing for Q1 2018, filed 9 May 2018.